Literature DB >> 20501856

ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA.

Hiroyuki Kawagishi1, Hideaki Nakamura, Mitsuo Maruyama, Shuki Mizutani, Kazushi Sugimoto, Masatoshi Takagi, Masataka Sugimoto.   

Abstract

Vascular endothelial growth factor A (VEGFA) is a specific mitogen for vascular endothelial cells that plays a critical role in cancer neoangiogenesis. Here, we report that the nucleolar tumor suppressor p19(ARF) suppresses VEGFA expression, acting at the level of mRNA translation without affecting the transcription of the VEGFA gene. Translational repression of VEGFA mRNA by p19(ARF) does not require p53, a major target of the ARF tumor suppressor pathway, but instead correlates with binding to nucleophosmin/B23. Maintaining VEGFA expression relies on nucleophosmin/B23, and downregulating this protein by RNAi or p19(ARF) leads to translational repression of VEGFA. p19(ARF) inhibits VEGFA-dependent tumor angiogenesis in nude mice. Additionally, p14(ARF) expression and microvessel density are inversely correlated in human colon carcinomas. Taken together, our results define a mechanism by which the ARF tumor suppressor targets the translational repression of specific oncogenes during neoplastic transformation. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501856     DOI: 10.1158/0008-5472.CAN-10-0368

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury.

Authors:  David H Lee; Jesse M Wolstein; Basu Pudasaini; Matthew Plotkin
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

Review 2.  Effects of aging on angiogenesis.

Authors:  Johanna Lähteenvuo; Anthony Rosenzweig
Journal:  Circ Res       Date:  2012-04-27       Impact factor: 17.367

3.  miR-34a is essential for p19(Arf)-driven cell cycle arrest.

Authors:  Nida Iqbal; Jie Mei; Jing Liu; Stephen X Skapek
Journal:  Cell Cycle       Date:  2014-01-08       Impact factor: 4.534

4.  P19ARF and RasV¹² offer opposing regulation of DHX33 translation to dictate tumor cell fate.

Authors:  Yandong Zhang; Anthony J Saporita; Jason D Weber
Journal:  Mol Cell Biol       Date:  2013-02-11       Impact factor: 4.272

5.  P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3.

Authors:  Abdessamad Zerrouqi; Beata Pyrzynska; Maria Febbraio; Daniel J Brat; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

6.  Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms.

Authors:  Danielle B Ulanet; Douglas Hanahan
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

7.  ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis.

Authors:  Jason T Forys; Catherine E Kuzmicki; Anthony J Saporita; Crystal L Winkeler; Leonard B Maggi; Jason D Weber
Journal:  Cell Rep       Date:  2014-04-13       Impact factor: 9.423

8.  Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the  receptor protein of CRL2Prame complex.

Authors:  Wenjuan Zhang; Lihui Li; Lili Cai; Yupei Liang; Junfeng Xu; Yue Liu; Lisha Zhou; Chen Ding; Yanmei Zhang; Hu Zhao; Jun Qin; Zhimin Shao; Wenyi Wei; Lijun Jia
Journal:  Cell Death Differ       Date:  2021-01-27       Impact factor: 15.828

Review 9.  Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.

Authors:  Bryan E Strauss; Gissele Rolemberg Oliveira Silva; Igor de Luna Vieira; Otto Luiz Dutra Cerqueira; Paulo Roberto Del Valle; Ruan Felipe Vieira Medrano; Samir Andrade Mendonça
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365

Review 10.  Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game.

Authors:  Paqui G Través; Alfonso Luque; Sonsoles Hortelano
Journal:  Mediators Inflamm       Date:  2012-12-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.